Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about a recent article by Luis Paz-Ares et al. published in The Lancet:
“FDA approves lurbinectedin plus atezolizumab as maintenance therapy for ES- SCLC based on IMForte study.
- important option to improve survival (mOS 13.2 vs 10.6 mos ( HR 0.73) in a fast moving cancer
- but not every patients is fit to tolerate chemo early.
Is early chemo toxicity worth it
Yes for fit patients.”
Title: Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Authors: Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, Solange Peters, Roy S Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Ali Nahit Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung-Ying Yang, Yasemin Kemal, Marcus Ballinger, Vaikunth Cuchelkar, Vilma Graupner, Ya-Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Robert Iannone, Martin Reck
Read the Full Article on The Lancet
More posts featuring Estela Rodriguez.
